Roche is a Switzerland‐based global healthcare company specializing in pharmaceuticals and diagnostics. Established in 1896 and headquartered in Basel, it operates through two core divisions: Pharmaceuticals, which develops and markets prescription medicines to treat a range of diseases, and Diagnostics, which designs and manufactures laboratory instruments, point-of-care testing systems and reagents. Roche is known for its strong emphasis on research and development, particularly in oncology and personalized medicine, and for integrating companion diagnostics into its drug development process.
In its Pharmaceuticals division, Roche focuses on targeted therapies and biologics for cancer, immunological disorders, neuroscience and rare diseases. The company’s portfolio includes several leading oncology treatments that address solid tumors and hematological malignancies, as well as therapies for multiple sclerosis, rheumatoid arthritis and other chronic conditions. Roche’s strategy emphasizes precision medicine, leveraging biomarkers and genetic profiling to tailor treatments to individual patients.
The Diagnostics unit provides instruments and tests for use in hospitals, laboratories and point-of-care settings. Its offerings span molecular diagnostics, tissue diagnostics, immunoassays, clinical chemistry and diabetes care through the Accu-Chek line. Roche’s diagnostic solutions are designed to support early disease detection, monitoring and treatment decisions, underpinning its integrated approach to healthcare.
Roche serves healthcare markets in more than 100 countries worldwide. The group has pursued strategic acquisitions and partnerships—most notably fully integrating Genentech in 2009—to bolster its research capabilities. Under the leadership of CEO Thomas Schinecker and Chairman Christoph Franz, Roche continues to invest significantly in innovation, aiming to address unmet medical needs and advance personalized healthcare.
AI Generated. May Contain Errors.
Free RHHBY Stock Alerts